Of note, although prescription of anti‐tumor necrosis factor or anti‐interleukin‐17A/receptor A biologics is difficult due to the greater risk of infection in older patients with GPP, the use of anti‐interleukin‐23 biologics could be higher than the numbers reflected in this study because these were approved in 2018. This evidence concerns the gene TNF and infection.